Furthermore, 8 studies tackling blood-based MS-MRD detection demonstrated up to 1,000-fold higher sensitivity than traditional immunofixation electrophoresis, identified biochemical relapse 2-11 months earlier, and achieved high concordance with bone marrow-based assays (NGS/NGF).<h4>Conclusion</h4>In conclusion, quantitative MS profiling provides a high-resolution molecular lens that significantly refines MM risk stratification beyond static staging. The gene discussed is NGF; the disease is Miyoshi myopathy.